TW201517920A - 交聯明膠撐體及使用其之生理活性物質控制釋放用撐體 - Google Patents
交聯明膠撐體及使用其之生理活性物質控制釋放用撐體 Download PDFInfo
- Publication number
- TW201517920A TW201517920A TW103114560A TW103114560A TW201517920A TW 201517920 A TW201517920 A TW 201517920A TW 103114560 A TW103114560 A TW 103114560A TW 103114560 A TW103114560 A TW 103114560A TW 201517920 A TW201517920 A TW 201517920A
- Authority
- TW
- Taiwan
- Prior art keywords
- support
- crosslinked gelatin
- physiologically active
- active substance
- gelatin
- Prior art date
Links
- 108010010803 Gelatin Proteins 0.000 title claims abstract description 163
- 229920000159 gelatin Polymers 0.000 title claims abstract description 163
- 235000019322 gelatine Nutrition 0.000 title claims abstract description 163
- 235000011852 gelatine desserts Nutrition 0.000 title claims abstract description 163
- 239000008273 gelatin Substances 0.000 title claims abstract description 162
- 239000013543 active substance Substances 0.000 title claims abstract description 81
- 238000013270 controlled release Methods 0.000 title claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000000717 retained effect Effects 0.000 claims abstract description 10
- 239000002245 particle Substances 0.000 claims description 50
- 239000000126 substance Substances 0.000 claims description 44
- 238000000354 decomposition reaction Methods 0.000 claims description 37
- 230000005251 gamma ray Effects 0.000 claims description 9
- 238000001179 sorption measurement Methods 0.000 description 49
- 238000004132 cross linking Methods 0.000 description 43
- 230000000694 effects Effects 0.000 description 22
- 238000005259 measurement Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000003102 growth factor Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000006065 biodegradation reaction Methods 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011148 porous material Substances 0.000 description 5
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 238000010382 chemical cross-linking Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229960000907 methylthioninium chloride Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000010102 embolization Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004931 aggregating effect Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012897 dilution medium Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002338 electrophoretic light scattering Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Laminated Bodies (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013089142A JP2014210756A (ja) | 2013-04-22 | 2013-04-22 | 架橋ゼラチン担体およびそれを用いた生理活性物質徐放担体 |
| JP2013089143A JP2014210757A (ja) | 2013-04-22 | 2013-04-22 | 架橋ゼラチン担体およびそれを用いた生理活性物質徐放担体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201517920A true TW201517920A (zh) | 2015-05-16 |
Family
ID=50489016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103114560A TW201517920A (zh) | 2013-04-22 | 2014-04-22 | 交聯明膠撐體及使用其之生理活性物質控制釋放用撐體 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9351934B2 (https=) |
| EP (1) | EP2796127A1 (https=) |
| KR (1) | KR20140126264A (https=) |
| CN (1) | CN104109252A (https=) |
| AU (1) | AU2014202182A1 (https=) |
| CA (1) | CA2849472A1 (https=) |
| IN (1) | IN2014CH02034A (https=) |
| RU (1) | RU2014115991A (https=) |
| TW (1) | TW201517920A (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11207258B2 (en) | 2016-01-25 | 2021-12-28 | Suntory Holdings Limited | Capsule containing functional substance and method for manufacturing said capsule |
| CN110876812A (zh) * | 2019-12-06 | 2020-03-13 | 赛克赛斯生物科技股份有限公司 | 明胶海绵栓塞剂及其制备方法和应用、治疗血管疾病或肿瘤的药物 |
| CN111269444A (zh) * | 2020-01-22 | 2020-06-12 | 苏州新丝原生物科技有限公司 | 一种交联微球及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998003203A1 (fr) | 1996-07-19 | 1998-01-29 | Yamanouchi Pharmaceutical Co., Ltd. | Particules poreuses insolubles dans l'eau, constituees de substances biocompatibles et leur procede de production |
| DE60229399D1 (de) | 2001-07-18 | 2008-11-27 | Medgel Corp | Hgf-hydrogel-zubereitungen mit verzögerter freisetzung |
| JP2004115413A (ja) * | 2002-09-25 | 2004-04-15 | Yasuhiko Tabata | 冠状動脈狭窄または閉塞治療用徐放性製剤 |
| US20110229580A1 (en) | 2010-03-22 | 2011-09-22 | Indian Institute of Technology Bombay, School of Biosciences and Bioengineering | Compositions and methods for nano-in-micro particles |
-
2014
- 2014-04-17 CA CA2849472A patent/CA2849472A1/en not_active Abandoned
- 2014-04-18 US US14/256,134 patent/US9351934B2/en active Active
- 2014-04-21 IN IN2034CH2014 patent/IN2014CH02034A/en unknown
- 2014-04-21 RU RU2014115991/15A patent/RU2014115991A/ru not_active Application Discontinuation
- 2014-04-22 CN CN201410163492.6A patent/CN104109252A/zh active Pending
- 2014-04-22 EP EP14165440.0A patent/EP2796127A1/en not_active Withdrawn
- 2014-04-22 AU AU2014202182A patent/AU2014202182A1/en not_active Abandoned
- 2014-04-22 TW TW103114560A patent/TW201517920A/zh unknown
- 2014-04-22 KR KR1020140047889A patent/KR20140126264A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014115991A (ru) | 2015-10-27 |
| US9351934B2 (en) | 2016-05-31 |
| KR20140126264A (ko) | 2014-10-30 |
| CN104109252A (zh) | 2014-10-22 |
| AU2014202182A1 (en) | 2014-11-06 |
| CA2849472A1 (en) | 2014-10-22 |
| US20140316013A1 (en) | 2014-10-23 |
| IN2014CH02034A (https=) | 2015-07-03 |
| EP2796127A1 (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103037847B (zh) | 用于制备干燥、稳定的止血组合物的方法 | |
| CN103037845B (zh) | 用于制备干燥、稳定的止血组合物的方法 | |
| Möbus et al. | Zinc–alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying | |
| JP6195569B2 (ja) | 止血組成物 | |
| CN102917691A (zh) | 用于生产干燥、稳定的止血组合物的方法 | |
| JP2014058466A (ja) | ゼラチン粒子およびその用途、ならびに生理活性物質投与用デバイス | |
| TW201517920A (zh) | 交聯明膠撐體及使用其之生理活性物質控制釋放用撐體 | |
| CN105169476B (zh) | 一种医用原位凝胶的制备方法及其应用 | |
| Cheaburu-Yilmaz et al. | Polysaccharide containing gels for pharmaceutical applications | |
| JP2014218464A (ja) | 均一分散可能な架橋ゼラチン粒子集合体 | |
| JP2014210757A (ja) | 架橋ゼラチン担体およびそれを用いた生理活性物質徐放担体 | |
| JP2014210756A (ja) | 架橋ゼラチン担体およびそれを用いた生理活性物質徐放担体 | |
| Lal et al. | Formulation and optimization of 5-fluorouracil loaded chitosan nanoparticles employing central composite design | |
| RU2665367C2 (ru) | Пероральная система доставки вещества белковой природы (варианты), защитная оболочка системы доставки (варианты) | |
| Dhiman | Hydrocolloid-based hydrogels in drug delivery | |
| Gebel et al. | Evaluation of somatropin release from chitosan and methylcellulose hydrogels: influence of hydrogel composition and phosvitin on the release profile | |
| TW201818923A (zh) | 醫藥賦形劑組成物之血管栓塞用親水性微粒 | |
| Ding et al. | Preparation and characterization of cyclophosphamide-loaded chitosan microspheres | |
| US20160151286A1 (en) | Hydrophilic Microparticles, Drug-Delivery Material, Method For Manufacturing Thereof And Methods For Delivery of A Drug-Delivery Composition | |
| CN115844813A (zh) | 可负载化疗药物的丙三醇包裹锰离子均相交联海藻酸钠缓释水凝胶及其制备方法与应用 | |
| JP2020125279A (ja) | ナノ粒子の製造方法 | |
| CN118766906A (zh) | 包含替莫唑胺的稳定的抗肿瘤药物组合物，以及该组合物的制备方法 |